-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At 7 pm on December 15th, 2021, the PNH regional series of “Breaking the Array” was successfully held online.
This meeting specially invited Professor Wang Shunqing from Guangzhou First People’s Hospital as the chairman of the conference, and Zhang Qing from Guangdong Second People’s Hospital The professor and Professor He Chuan from West China Hospital of Sichuan University respectively shared the current status of PNH diagnosis and treatment and China’s unmet need for treatment, C5 complement inhibitor treatment of PNH and the new generation of C5 complement inhibitor Crovalimab, and the current status and treatment of PNH The progress was discussed in depth
.
At 7 o'clock in the evening, with the introduction of paroxysmal nocturnal hemoglobinuria (PNH) by the chairman of the conference, the curtain of the meeting was officially opened
.
Professor Wang Shunqing introduced that there is still a lack of domestic treatment drugs for PNH.
The quality of life of patients is not high.
The hemolysis of most patients is not controlled.
Many patients still need to rely on hormones, blood transfusion and other means for maintenance
.
Although hematopoietic stem cell transplantation is one of the treatment methods, the disease still cannot be cured due to various reasons
.
The current demand for clinical treatment is largely unmet
.
Subsequently, Professor Zhang Qing further analyzed the current status of PNH diagnosis and treatment
.
Although PNH is a benign hematological disease, due to the lack of effective treatment, compared with some inert hematological malignancies, the survival rate of PNH is still lower.
At present, the 10-year survival rate of PNH patients in China is about 70%
.
The typical symptoms of PNH have three main aspects: intravascular hemolysis, potential hematopoietic failure, thrombosis tendency, and some common symptoms, such as fatigue, anemia, and so on
.
For PNH treatment goals, there are mainly four aspects: 1) Stable control of hematological indicators: long-term stable control of intravascular hemolysis, reduce breakthrough hemolysis, improve anemia, and avoid blood transfusion; 2) reduce symptoms and improve complications; 3) improve quality of life, and prolong survival; 4), and other modes of administration, for example, overcoming C5 polymorphism
.
However, the current treatment for PNH in China is very limited.
The conventional treatment is glucocorticoids, mainly to control hemolysis, but the effect of the treatment is not satisfactory
.
And PNH, as a benign disease, is more cautious when considering chemotherapy and transplantation
.
In foreign countries, C5 complement inhibitors have become the standard treatment for PNH, which can effectively control hemolysis, improve complications, and prolong patient survival
.
However, it is not yet reachable in China
.
Therefore, there are still many treatment needs for PNH patients in China that have not been met: 1) Poor hemolysis control: There is no effective treatment to stably control intravascular hemolysis for a long time; 2) Symptoms and complications have not been effectively improved: the underlying cause (complement Activation and hemolysis) have not been improved, the symptoms of PNH and the risk of complications such as PNH-related thrombosis and renal insufficiency are higher; 3) The patient's survival status is poor
.
Therefore, clinicians need more treatment methods to better solve PNH-related disease problems
.
Professor He Chuan from West China Hospital of Sichuan University then brought you the introduction of C5 complement inhibitor and a new generation of C5 complement inhibitor Crovalimab
.
First, Professor He Chuan shared a set of clinical characteristics data on Chinese PNH patients published by Professor Han Bing's team on EHA this year
.
Studies have shown that in the Chinese population, PNH patients are predominantly classic and bone marrow failure
.
In terms of clinical characteristics and overall survival, thrombosis (P=0.
032) is the only prognostic factor for BMF/PNH; disease course (P=0.
005) and renal insufficiency (P=0.
011) are the prognostic factors for patients with classic PNH
.
Then we saw relevant foreign data, C5 complement inhibitors can improve the survival of PNH patients
.
For PNH patients, C5 complement inhibitors are a landmark treatment and improvement in efficacy
.
The first-generation C5 complement inhibitor eculizumab treatment improves hematology in PNH patients, but there are some limitations: 1) Some patients have incomplete complement inhibition and still have intravascular hemolysis, 32%-49% of patients Blood transfusion is needed; 2) Eculizumab is not effective for patients with C5 polymorphism; 3) Eculizumab needs to be administered by intravenous infusion; 4) The accessibility is poor and it is currently unavailable in many parts of the world Eculizumab treatment
.
In order to further improve the limitations of C5 complement inhibitors, a new generation of C5 complement inhibitor Crovalimab is ushered in
.
Through engineering transformation, the new generation of C5 complement inhibitors has more advantages: higher affinity to C5, preferential antibody uptake, pH-dependent antigen-antibody binding, and circulating antibodies can bind to C5 multiple times
.
Traditional antibodies have only one antigen binding ability and a short half-life.
After targeting membrane surface antigens or soluble antigens, the cells are endocytosed and quickly cleared by the body, requiring larger doses or more frequent administration
.
Circulating antibodies have multiple antigen binding capabilities, prolonged half-life, reduced antibody clearance, and reduced dosage
.
The results of the Crovalimab 1/2 open-label adaptive clinical trial COMPOSER study showed that in the newly-treated and C5 inhibitor-treated PNH patients, safety and tolerability were good, and there were no treatment-related SAEs or AEs that led to the termination of the study
.
In terms of curative effect, Crovalimab can block complement activity and control intravascular hemolysis; Hb in the newly treated population rises, and Hb remains stable in the C5 complement treatment population; the overall blood transfusion demand decreases during the treatment of Crovalimab; and there is no response to eculizumab C5 polymorphism is still effective in patients with C5 polymorphism; in terms of administration method, Crovalimab can be maintained by subcutaneous injection every four weeks
.
At present, Crovalimab is carrying out multiple phase III clinical trials for PNH, and the availability of drugs is just around the corner
.
Afterwards, the meeting entered the discussion stage, and several professors continued to exchange views on PNH diagnosis and treatment related content and treatment methods
.
Finally, Professor Wang Shunqing made a summary of the conference.
C5 inhibitors are very meaningful for the control of PNH patients' disease and the improvement of quality of life.
He also expressed the hope that C5 complement inhibitors will be available to Chinese patients as soon as possible
.
Finally, the meeting ended smoothly and satisfactorily
.
Scan the QR code, look back at the live broadcast of the conference, stamp "Read the original text", check back at the live broadcast
This meeting specially invited Professor Wang Shunqing from Guangzhou First People’s Hospital as the chairman of the conference, and Zhang Qing from Guangdong Second People’s Hospital The professor and Professor He Chuan from West China Hospital of Sichuan University respectively shared the current status of PNH diagnosis and treatment and China’s unmet need for treatment, C5 complement inhibitor treatment of PNH and the new generation of C5 complement inhibitor Crovalimab, and the current status and treatment of PNH The progress was discussed in depth
.
At 7 o'clock in the evening, with the introduction of paroxysmal nocturnal hemoglobinuria (PNH) by the chairman of the conference, the curtain of the meeting was officially opened
.
Professor Wang Shunqing introduced that there is still a lack of domestic treatment drugs for PNH.
The quality of life of patients is not high.
The hemolysis of most patients is not controlled.
Many patients still need to rely on hormones, blood transfusion and other means for maintenance
.
Although hematopoietic stem cell transplantation is one of the treatment methods, the disease still cannot be cured due to various reasons
.
The current demand for clinical treatment is largely unmet
.
Subsequently, Professor Zhang Qing further analyzed the current status of PNH diagnosis and treatment
.
Although PNH is a benign hematological disease, due to the lack of effective treatment, compared with some inert hematological malignancies, the survival rate of PNH is still lower.
At present, the 10-year survival rate of PNH patients in China is about 70%
.
The typical symptoms of PNH have three main aspects: intravascular hemolysis, potential hematopoietic failure, thrombosis tendency, and some common symptoms, such as fatigue, anemia, and so on
.
For PNH treatment goals, there are mainly four aspects: 1) Stable control of hematological indicators: long-term stable control of intravascular hemolysis, reduce breakthrough hemolysis, improve anemia, and avoid blood transfusion; 2) reduce symptoms and improve complications; 3) improve quality of life, and prolong survival; 4), and other modes of administration, for example, overcoming C5 polymorphism
.
However, the current treatment for PNH in China is very limited.
The conventional treatment is glucocorticoids, mainly to control hemolysis, but the effect of the treatment is not satisfactory
.
And PNH, as a benign disease, is more cautious when considering chemotherapy and transplantation
.
In foreign countries, C5 complement inhibitors have become the standard treatment for PNH, which can effectively control hemolysis, improve complications, and prolong patient survival
.
However, it is not yet reachable in China
.
Therefore, there are still many treatment needs for PNH patients in China that have not been met: 1) Poor hemolysis control: There is no effective treatment to stably control intravascular hemolysis for a long time; 2) Symptoms and complications have not been effectively improved: the underlying cause (complement Activation and hemolysis) have not been improved, the symptoms of PNH and the risk of complications such as PNH-related thrombosis and renal insufficiency are higher; 3) The patient's survival status is poor
.
Therefore, clinicians need more treatment methods to better solve PNH-related disease problems
.
Professor He Chuan from West China Hospital of Sichuan University then brought you the introduction of C5 complement inhibitor and a new generation of C5 complement inhibitor Crovalimab
.
First, Professor He Chuan shared a set of clinical characteristics data on Chinese PNH patients published by Professor Han Bing's team on EHA this year
.
Studies have shown that in the Chinese population, PNH patients are predominantly classic and bone marrow failure
.
In terms of clinical characteristics and overall survival, thrombosis (P=0.
032) is the only prognostic factor for BMF/PNH; disease course (P=0.
005) and renal insufficiency (P=0.
011) are the prognostic factors for patients with classic PNH
.
Then we saw relevant foreign data, C5 complement inhibitors can improve the survival of PNH patients
.
For PNH patients, C5 complement inhibitors are a landmark treatment and improvement in efficacy
.
The first-generation C5 complement inhibitor eculizumab treatment improves hematology in PNH patients, but there are some limitations: 1) Some patients have incomplete complement inhibition and still have intravascular hemolysis, 32%-49% of patients Blood transfusion is needed; 2) Eculizumab is not effective for patients with C5 polymorphism; 3) Eculizumab needs to be administered by intravenous infusion; 4) The accessibility is poor and it is currently unavailable in many parts of the world Eculizumab treatment
.
In order to further improve the limitations of C5 complement inhibitors, a new generation of C5 complement inhibitor Crovalimab is ushered in
.
Through engineering transformation, the new generation of C5 complement inhibitors has more advantages: higher affinity to C5, preferential antibody uptake, pH-dependent antigen-antibody binding, and circulating antibodies can bind to C5 multiple times
.
Traditional antibodies have only one antigen binding ability and a short half-life.
After targeting membrane surface antigens or soluble antigens, the cells are endocytosed and quickly cleared by the body, requiring larger doses or more frequent administration
.
Circulating antibodies have multiple antigen binding capabilities, prolonged half-life, reduced antibody clearance, and reduced dosage
.
The results of the Crovalimab 1/2 open-label adaptive clinical trial COMPOSER study showed that in the newly-treated and C5 inhibitor-treated PNH patients, safety and tolerability were good, and there were no treatment-related SAEs or AEs that led to the termination of the study
.
In terms of curative effect, Crovalimab can block complement activity and control intravascular hemolysis; Hb in the newly treated population rises, and Hb remains stable in the C5 complement treatment population; the overall blood transfusion demand decreases during the treatment of Crovalimab; and there is no response to eculizumab C5 polymorphism is still effective in patients with C5 polymorphism; in terms of administration method, Crovalimab can be maintained by subcutaneous injection every four weeks
.
At present, Crovalimab is carrying out multiple phase III clinical trials for PNH, and the availability of drugs is just around the corner
.
Afterwards, the meeting entered the discussion stage, and several professors continued to exchange views on PNH diagnosis and treatment related content and treatment methods
.
Finally, Professor Wang Shunqing made a summary of the conference.
C5 inhibitors are very meaningful for the control of PNH patients' disease and the improvement of quality of life.
He also expressed the hope that C5 complement inhibitors will be available to Chinese patients as soon as possible
.
Finally, the meeting ended smoothly and satisfactorily
.
Scan the QR code, look back at the live broadcast of the conference, stamp "Read the original text", check back at the live broadcast
